Results 241 to 250 of about 22,784 (283)

Cardiovascular Disease and Diabetes: A New Challenge in the Treatment and Management. [PDF]

Int J Mol Sci
Riccioni G, Notarangelo C, Riccioni M, D'Orazio N.   +3 more
europepmc   +1 more source

Risk of lower extremity complications with GLP-1 receptor agonists, SGLT2 inhibitors, and DPP-4 inhibitors in peripheral artery disease. [PDF]

Diabetes Res Clin Pract
Hong AT, Lin F, Luu IY, Shin L, Han SM, Armstrong DG, Tan TW.   +6 more
europepmc   +1 more source

A case series of vildagliptin-associated bullous pemphigoid - Rare side effect.

Indian J Pharmacol
Shahi MK, Ashwin JV, Singh A, Gupta S, Surya K.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Fluoropyrrolidine amides as dipeptidyl peptidase IV inhibitors

Bioorganic & Medicinal Chemistry Letters, 2004
Amides derived from fluorinated pyrrolidines and 4-substituted cyclohexylglycine analogues have been prepared and evaluated as inhibitors of dipeptidyl dipeptidase IV (DP-IV). Analogues which incorporated (S)-3-fluoropyrrolidine showed good selectivity for DP-IV over quiescent cell proline dipeptidase (QPP).
Charles G, Caldwell, Ping, Chen, Jiafang, He, Emma R, Parmee, Barbara, Leiting, Frank, Marsilio, Reshma A, Patel, Joseph K, Wu, George J, Eiermann, Aleksandr, Petrov, Huaibing, He, Kathryn A, Lyons, Nancy A, Thornberry, Ann E, Weber   +13 more
openaire   +3 more sources

Recent patents of dipeptidyl peptidase IV inhibitors

Expert Opinion on Therapeutic Patents, 2011
The serine exopeptidase DPP IV is a dual protein able to work as an enzyme and an interacting protein. The incretin molecules glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are hydrolyzed by DPP IV into inactive forms, which are unable to promote insulin secretion.
Laura, Mendieta, Teresa, Tarrago, Ernest, Giralt   +2 more
openaire   +2 more sources

Azetidine-Based Inhibitors of Dipeptidyl Peptidase IV (DPP IV)

Current Topics in Medicinal Chemistry, 2007
The structure-activity relationships of azetidine-based DPP IV inhibitors will be discussed in detail in the following review. The azetidine-based DPP IV inhibitors can be divided into three main subtypes, the 2-cyanoazetidines, 3-fluoroazetidines and 2-ketoazetidines.
Dana, Ferraris, Sergei, Belyakov, Weixing, Li, Eddie, Oliver, Yao-Sen, Ko, David, Calvin, Susan, Lautar, Bert, Thomas, Camilo, Rojas   +8 more
openaire   +2 more sources

Diprolyl nitriles as potent dipeptidyl peptidase IV inhibitors

Bioorganic & Medicinal Chemistry Letters, 2005
Dipeptidyl peptidase IV (DPP4) is a multifunctional type II transmembrane serine peptidase which regulates various physiological processes, most notably plasma glucose homeostasis by cleaving peptide hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
Guohua, Zhao, Prakash C, Taunk, David R, Magnin, Ligaya M, Simpkins, Jeffrey A, Robl, Aiying, Wang, James G, Robertson, Jovita, Marcinkeviciene, Doree F, Sitkoff, Rex A, Parker, Mark S, Kirby, Lawrence G, Hamann   +11 more
openaire   +3 more sources

Potent non-nitrile dipeptidic dipeptidyl peptidase IV inhibitors

Bioorganic & Medicinal Chemistry Letters, 2007
The synthesis and structure-activity relationships of novel dipeptidyl peptidase IV inhibitors replacing the classical cyanopyrrolidine P1 group with other small nitrogen heterocycles are described. A unique potency enhancement was achieved with beta-branched natural and unnatural amino acids, particularly adamantylglycines, linked to a (2S,3R)-2,3 ...
Ligaya M, Simpkins, Scott, Bolton, Zulan, Pi, James C, Sutton, Chet, Kwon, Guohua, Zhao, David R, Magnin, David J, Augeri, Timur, Gungor, David P, Rotella, Zhong, Sun, Yajun, Liu, William S, Slusarchyk, Jovita, Marcinkeviciene, James G, Robertson, Aiying, Wang, Jeffrey A, Robl, Karnail S, Atwal, Robert L, Zahler, Rex A, Parker, Mark S, Kirby, Lawrence G, Hamann   +21 more
openaire   +2 more sources